AFP and Encephalopathy: The IL-6 promoter methylation level showed no significant difference in HBeAg (P=0.314), AFP (Ng/mL) (p=0.532), primary tumor number (P=0.801), vascular invasion (P=0.658), CTP staging (P=0.308), BCLC staging (P=0.389), ascites (P=0.212), encephalopathy (P=0.082).